LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

4.27 4.15

Buy Sell

Overview

Share price change

24h

Current

Min

4.01

Max

4.3

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	-1.9M -36M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+245.29% upside

Market Stats
By TradingEconomics
Market Cap	-18M 237M
Previous open	0.12
Previous close	4.27

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lis 2025, 18:59 UTC

Major Market Movers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 lis 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 lis 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 lis 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 lis 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 lis 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Rev $2.6B >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q EPS $4.02 >TCOM

17 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Adj EPS 26c >JHX

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 lis 2025, 21:39 UTC

Earnings

James Hardie Industries 2Q Sales $1.29B >JHX

17 lis 2025, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 21:38 UTC

Earnings

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q EPS BRL2.47 >XP

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q Rev BRL4.67B >XP

17 lis 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lis 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 lis 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 lis 2025, 19:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 18:20 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 lis 2025, 16:45 UTC

Acquisitions, Mergers, Takeovers

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 lis 2025, 16:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 16:15 UTC

Earnings

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 lis 2025, 15:40 UTC

Acquisitions, Mergers, Takeovers

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 lis 2025, 15:22 UTC

Acquisitions, Mergers, Takeovers

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 lis 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

245.29% upside

12 Months Forecast

Average 13.57 USD 245.29%

High 25 USD

Low 8 USD

Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.